In the context of combining/sequencing local treatments and TKI treatments for BM in the patients with driver mutant NSCLC, when survival-related factors are evaluated either considering the EGFR mutant and ALK positive patient groups separately or the entire group, having 1–3 BMs and isolated BMs were associated with significantly better iPFS and OS data, in line with the literature21. This evidence concerns the gene EGFR and non-small cell lung carcinoma.